Viibryd Approval History
- FDA approved: Yes (First approved January 21st, 2011)
- Brand name: Viibryd
- Generic name: vilazodone
- Dosage form: Tablets
- Company: Allergan plc
- Treatment for: Depression, Major Depressive Disorder
Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).
Development History and FDA Approval Process for Viibryd
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.